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http://dx.doi.org/10.1016/j.stemcr.2016.08.018SUMMARYHuntington’s disease (HD) is characterized by fatalmotoric failures induced by loss of striatalmedium spiny neurons. Neuronal cell death
has been linked to impaired expression and axonal transport of the neurotrophin BDNF (brain-derived neurotrophic factor). By trans-
planting embryonic stem cell-derived neural progenitors overexpressing BDNF, we combined cell replacement and BDNF supply as a
potential HD therapy approach. Transplantation of purified neural progenitors was analyzed in a quinolinic acid (QA) chemical and
two genetic HD mouse models (R6/2 and N171-82Q) on the basis of distinct behavioral parameters, including CatWalk gait analysis.
Explicit rescue of motor function by BDNF neural progenitors was found in QA-lesioned mice, whereas genetic mouse models displayed
only minor improvements. Tumor formation was absent, and regeneration was attributed to enhanced neuronal and striatal differenti-
ation. In addition, adult neurogenesis was preserved in a BDNF-dependentmanner. Our findings provide significant insight for establish-
ing therapeutic strategies for HD to ameliorate neurodegenerative symptoms.INTRODUCTION
The neurodegenerative disease Huntington’s disease (HD)
is characterized by dramatic motor dysfunction, cognitive
decline, and psychiatric symptoms, which lead to progres-
sive dementia and death approximately 15–20 years after
onset (Landles and Bates, 2004). HD is an autosomal domi-
nant inheritable disease, caused by mutations in the hun-
tingtin (HTT) gene, leading to an increased number of
polyglutamine repeats in the encoded protein (McMurray,
2001). How mutant HTT protein causes neuronal dysfunc-
tion and neurodegeneration has not yet been understood
in detail, and besides the existence of some symptomatic
treatments, so far there is no causal therapy available for pa-
tients. Numerous laboratories showed that in a large num-
ber of HD mouse models BDNF or BDNF/TRKB signaling is
strongly reduced due to amutant htt-mediatedmechanism
(Plotkin et al., 2014; Zuccato and Cattaneo, 2009). Besides
causing changes in vesicular transport of BDNF (Gauthier
et al., 2004), mutant HTT has been described to cause
transcriptional downregulation of the BDNF gene through
translocation of RE1 silencing transcription factor to the
nucleus (Buckley et al., 2010). In addition to HD mouse
models, a systematic and quantitative assessment of
BDNF levels in human cerebral cortex samples, examined
post mortem, confirmed that the production of this neuro-
trophin was impaired in the brains of HD patients (Zuccato
et al., 2008). As striatal medium spiny neurons (MSNs)
depend on BDNF activity, a number of studies attempted
striatal neuroprotection by providing exogenous BDNF
delivered to the diseased rodent striatum either by adenoas-Stem Cell Re
This is an open access article under the Csociated viral transfer or by transplantation of diverse
genetically modified cell types (e.g., fibroblasts) (Connor
et al., 2016; Sari, 2011). Altogether these studies showed
enhanced neuroprotection, but no or only mild effects
on long-term functional improvement in HD rodent
models. On the other hand, cell transplantation as a prom-
ising therapeutic strategy, which aims to replace striatal
neurons, has yielded some preliminary, but only modest
and short-lived clinical benefits when using fetal neural
cells (Bachoud-Levi et al., 2006; Gallina et al., 2010). There-
fore, specifically embryonic stem cells (ESCs) and induced
pluripotent stem cells (iPSCs) are considered to be an
appropriate cell source, as ESCs can be differentiated
in vitro into an MSN-like phenotype (Aubry et al., 2008;
Danjo et al., 2011; Ma et al., 2012; Shin et al., 2012). How-
ever, their long-term survival, long-term functional
improvement, and safety in vivo still need to be proved.
In the present study, we aimed to establish a combina-
tion therapy approach composed of cellular replace-
ment by ESC-derived neural progenitors linked to BDNF
supply. For this reason, we have generated BDNF-overex-
pressing mouse ESCs by knockin technology that display
an enhanced neuronal and GABAergic differentiation
in vitro (Leschik et al., 2013). Very recently, we were able
to show that polysialylated neuronal cell adhesion mole-
cule (PSA-NCAM)-positive progenitors derived from these
ESCs lead to functional improvement when transplanted
into mice with contusion spinal cord injury (Butenscho¨n
et al., 2016). With small modifications to the published
protocol, which comprises magnetic-activated cell sorting
(MACS) technology for purification, we tested in this studyports j Vol. 7 j 693–706 j October 11, 2016 j ª 2016 The Author(s). 693
C BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
the efficiency and safety in three divergent HD mouse
models. At present, a variety of different HDmouse models
exist, chemically or genetically induced, whichmatchwith
some aspects of HD. However, until now none of them
perfectly recapitulates human neuropathological hall-
marks as well as progressive cognitive and motor impair-
ments. So far, genetic HD mouse models have been used
only in a few cell transplantation studies. In most cases,
cell transplantation was performed in toxin-lesioned
mice, in which vast neurodegeneration occurs. This is
clearly an advantage over genetic mouse models, which
harbor less neurotoxicity. In contrast, genetic accuracy is
missing in toxin-induced lesions and it is therefore ques-
tionable whether this represents an appropriate model sys-
tem to test therapeutics for human pathology. For this
reason, we decided to use besides the toxin-lesioned model
with quinolinic acid (QA) the two widely used transgenic
mouse lines R6/2 and N171-82Q, which differ in their
extent of pathological features and degree of impairment
(Ramaswamy et al., 2007). Typical behavioral assays for
eachHDmousemodel were chosen based on previous pub-
lications. We also included the automated gait analysis
system CatWalk as a very sensitive method for measuring
subtle changes in motor behavior. Here, we show that the
CatWalk assay is a valid method to address motor behavior
in the QA-lesion and N171-82Q mouse models. Cell trans-
plantation with purified BDNF-expressing neural progeni-
tors revealed an improved motor function in QA-lesioned
mice, whereas only subtle effects on motor behavior
were detected in both transgenic mouse lines. Therapeutic
effects of BDNF-expressing progenitors in the QA model
could be attributed to enhanced neuronal and striatal
in vivo differentiation compared with control cells.
Furthermore, tumor formation was completely absent, in
contrast to other studies (Aubry et al., 2008).RESULTS
Efficient In Vitro Preparation and Purification of
Neural Precursor Cells for Transplantation
Mouse ESCs either overexpressing BDNF-GFP or GFP as
control were differentiated as described previously via an
embryoid body protocol followed by neural lineage selec-
tion (Butenscho¨n et al., 2016). Cells were enriched for the
intermediate neural progenitor marker PSA-NCAM and
depleted of undifferentiated ESCs positive for stage-specific
embryonic antigen-1 (SSEA-1) by MACS (Figure 1A). Cells
were replated, and differentiation was induced by removal
of basic fibroblast growth factor. Three days later, cells were
analyzed by staining for multiple markers to ensure that
BDNF-GFP andGFP cells were in the same stage of differen-
tiation prior to transplantation (Figures 2A and 2B).694 Stem Cell Reports j Vol. 7 j 693–706 j October 11, 2016Cultured cells (n = 3 independent experiments) expressed
the neural stem cell markers Nestin (20.9% ± 3.2% BDNF-
GFP, 23.9% ± 1.4% GFP cells) and PSA-NCAM (76.2% ±
4.4% BDNF-GFP and 65.4% ± 3.1% GFP cells). Only
1.5% ± 0.6% of BDNF-GFP and 2.5% ± 0.7% of GFP cells
were positive for doublecortin (DCX). All neural progeni-
tors expressed forkhead box protein G1 (FOXG1), one of
the earliest markers of the telencephalic lineage. Few cells
expressed the neuronal marker microtubule-associated
protein 2 (MAP2) (1.3% ± 0.3% BDNF-GFP and 1.2% ±
0.1% GFP) and the astrocytic marker glial fibrillary acidic
protein (GFAP) (1.3% ± 0.3% BDNF-GFP and 2.8% ± 0.6%
GFP), whereas no cells expressed the oligodendrocytic
marker oligodendrocyte transcription factor 2 (OLIG2). A
fraction of proliferating cells was detectable by theM-phase
marker KI67 (14.1% ± 1.2% BDNF-GFP and 10.9% ± 0.2%
GFP neural progenitor cells [NPCs]), but all cells were posi-
tive for 5-bromo-20-deoxyuridine (BrdU) (Figure 2C). No
significant differences for any marker were detected be-
tween the two groups of cells. In vitro, BDNF-GFP cells
were detectable with GFP immunostaining (Figure 2D)
and showed BDNF-GFP-positive vesicles, while GFP NPCs
displayed a uniform staining of the whole cell. As already
shown in Butenscho¨n et al. (2016), BDNF-GFP signal was
barely detectable in vivo. Therefore, BrdU was used to label
cells for transplantation, which was carried out in three
different HD mouse models: QA lesion, R6/2, and N171-
82Q. Figure 1B depicts the experimental outline of the
transplantation studies with subsequent behavioral assays.
BDNF-GFP Cells Induce Locomotor Recovery in
QA-Lesioned Mice
First, we addressed the functional effect of transplanting
BDNF-GFP NPCs into the chemical HD mouse model
with QA-induced lesion. Therefore, NPCs were trans-
planted at an animal age of 10 weeks, and groups
(n = 10/group) were tested every other week for apomor-
phine-induced rotations (see experimental outline in
Figure 1B). Immediately prior to transplantation, animals
of all QA-lesioned groups displayed similar numbers of
net rotations, which were significantly different from
those mice that had only received a PBS injection instead
of QA (p < 0.001).
After transplantation and repeated testing over time,
QA-lesioned animals (QA + Hank’s balanced salt solution
[HBSS], QA + GFP NPCs, and QA + BDNF-GFP NPCs) ex-
hibited significantly higher net rotations at all time points
compared with non-lesioned animals (PBS + HBSS) (Fig-
ure 3A). Recovery became significant 8 weeks after trans-
plantation, when animals in the BDNF-GFP transplant
group displayed 85 ± 22.65 net rotations compared with
132.6 ± 19.84 in theQA-HBSS group (p = 0.005) (Figure 3B).
GFP cell-transplanted animals did not display significant
Figure 1. Experimental Outline of the
Study
(A) General concept. BDNF-GFP and GFP ESCs
were differentiated to NPCs and sorted by
MACS for a PSA-NCAM+/SSEA-1 population.
After 3 days of differentiation, cells were
transplanted into the striatum of three
different HD mouse models: the QA-
lesioned, R6/2, and N171-82Q mouse
models.
(B) Overview of mouse models and respec-
tive behavioral assays at distinct time points
of age.improvement of locomotor function compared with con-
trol animals (QA + HBSS) 8 weeks after transplantation
(Figure 3B).
Rotarod data showed similar results, with BDNF-GFP
cells improving motor function of QA-lesioned mice (Fig-
ure 3C). Mice with BDNF-GFP transplants improved in
their latency to fall and were not significantly different
(p = 0.144) when compared with non-lesioned control an-
imals during repeated testing. In contrast, GFP transplants
did not ameliorate motor function over time, as they still
differed significantly from the non-lesioned control group,
with p = 0.022 during repeated testing. However, when
looking at a single time point at 18 weeks of age (8 weeks
after transplantation), the mean latency of 153.2 ±
13.61 s detected for the GFP cell-transplanted group did
not significantly differ any longer from non-lesioned con-
trol animals (PBS + HBSS; 202.8 ± 13.31 s latency) (Fig-
ure 3D). Thismeans that also GFP cells exerted a significant
functional recovery, whichwas similar to the improvement
of BDNF-GFP cell-transplanted animals at 8 weeks after
transplantation, as no significant difference between both
groups was detected. Only HBSS vehicle-treated QA-ani-mals still displayed significantly lower motor performance
than the healthy control group (p = 0.023).
In addition to the analysis of motor performance by the
rotation and Rotarod assays, we established the use of the
CatWalk gait system in the QA-lesion HD model. Figure S1
graphically demonstrates distinct gait parameters, which
were significantly affected in QA-lesioned mice compared
with non-lesioned control animals, and Table S1 presents
quantitative data of these gait parameters. At 14 weeks of
age, QA-lesioned mice displayed significantly reduced
walk speed (PBS + HBSS 282.4 ± 16.2 mm/s, QA + HBSS
225.3 ± 7.4 mm/s; p = 0.009) and swing speed (e.g., PBS +
HBSS[left forepaw, LF] 623.7 ± 25.9 mm/s, QA + HBSS[LF]
534.7 ± 14.0 mm/s; p[LF] = 0.038) and enhanced swing
(e.g., PBS + HBSS[left hindpaw, LH] 0.1095 ± 0.0032 s,
QA +HBSS[LH] 0.1215 ± 0.0030 s; p[LH] = 0.018) compared
with non-lesioned control mice. At 18 weeks of age, addi-
tionally cadence (PBS + HBSS 18.6 ± 0.86 steps/s, QA +
HBSS 15.11 ± 0.62 steps/s; p = 0.005) and stride length
(e.g., PBS + HBSS[right forepaw, RF] 81.28 ± 0.80 mm,
QA + HBSS[RF] 67.13 ± 1.19 mm; p[RF] = 0.0001) were
significantly reduced, whereas stand (e.g., PBS + HBSS[RF]Stem Cell Reports j Vol. 7 j 693–706 j October 11, 2016 695
Figure 2. BDNF-GFP and GFP Cells Do Not Differ in Expression of Neural, Glial, and Neuronal Markers before Transplantation
(A) Generation of NPCs was analyzed after 3 days of differentiation after MACS by immunostaining for NESTIN, PSA-NCAM, KI67, DCX, MAP2,
GFAP, FOXG1, and OLIG2 (BDNF-GFP cells, all stained in red).
(B) Respective percentages of marker expression of all DAPI cells. No significant difference (p = 0.3656) between BDNF-GFP and GFP cells
was detected (n = 3 independent experiments).
(C) Overlay of fluorescent and bright-field microscopic images demonstrates that all cells were labeled with BrdU and hence proliferative.
(D) Anti-GFP immunocytochemistry of purified BDNF-GFP NPCs shows the vesicular distribution of BDNF throughout the cell, whereas in
GFP NPCs, GFP is detected in the whole cytoplasm.
Scale bars, 50 mm.0.1079 ± 0.0047 s, QA + HBSS[RF] 0.1440 ± 0.0057 s;
p[RF] = 0.001) and duty cycle (e.g., PBS + HBSS[RF]
51.60% ± 0.51%, QA + HBSS[RF] 55.60% ± 0.47%; p[RF] =
0.001) was significantly enhanced. Figure 3E further
demonstrates qualitatively in tabular representation
which gait parameters of which paw could be partially
rescued by either or both types of NPCs. In general,
measuring at 14weeks of age (4weeks after transplantation)
seemed to be more effective than at a later time point.
Here, swing (QA + GFP NPCs[LH] 0.1201 ± 0.0027 s, p[LH]
versus PBS + HBSS[LH] = 0.057) and swing speed (e.g.,
QA + GFP NPCs[LF] 582.00 ± 31.69 mm/s, p[LF] versus
PBS + HBSS[LF] = 0.109, QA + BDNF-GFP NPCs[LF]
546.59 ± 19.60 mm/s, p[LF] versus PBS + HBSS[LF] = 0.596)696 Stem Cell Reports j Vol. 7 j 693–706 j October 11, 2016were improved by either GFP cells alone or both cell types,
which was no longer measurable at 18 weeks of age. At
this time point, only duty cycle was positively affected by
GFP and BDNF-GFP NPCs (QA + GFP NPCs 55.05% ±
3.54%, p versus PBS + HBSS = 0.088; QA + BDNF-GFP
NPCs 54.97% ± 3.05%, p versus PBS + HBSS = 0.100).
CatWalk Gait Parameters of the R6/2 Model Are
Affected by Transplantation of NPCs
Next, we asked how transplantation ofNPCs affects pathol-
ogy in the transgenic R6/2mousemodel of HD. Themiddle
panel of Figure 1B describes the experimental outline with
cell transplantation into R6/2 animals (n = 10–12/group) at
5 weeks of age and consecutive behavioral assays until the
Figure 3. BDNF-GFP Cells Improve Locomotor Function in QA-
Lesioned Mice 8 Weeks after Transplantation
(A) Analysis of rotational behavior in response to apomorphine. At
all time points, non-lesioned animals (PBS + HBSS) displayed
significantly fewer rotations (*p < 0.05) than QA-lesioned (QA +
HBSS, QA + GFP NPCs, and QA + BDNF-GFP NPCs) animals.
(B) At an age of 18 weeks (8 weeks after transplantation), all
lesioned groups were different from the non-lesioned group (QA +
HBSS: p < 0.001; QA + GFP NPCs: p < 0.001; QA + BDNF-GFP NPCs:
p = 0.03). However, BDNF-GFP NPCs showed a highly significant
decrease in net rotations compared with untreated, lesioned
animals (**p = 0.005). Values represent mean ± SEM; xxxp < 0.001,
xp < 0.05 versus PBS + HBSS.
(C) Analysis of motor behavior on the Rotarod. An overall group
effect was observed (p = 0.006), without a significant interactionage of 12 weeks. Rotarod and hindlimb clasping, the two
mainly used assays for functional assessment of the R6/2
line, revealed no differences between NPC-transplanted
animals and vehicle control R6/2 animals (Figures 4A and
4B). Similar results were obtained with the grip strength
and open field test. Only thewild-type (WT) group behaved
significantly different compared with the transplanted
and non-transplanted R6/2 groups (Figures 4C and 4D).
Furthermore, body weight, an increase of which can be
taken as ameasure of physical recovery, was unchanged be-
tween R6/2 groups (Figure 4E). However, when we tested
animals in the CatWalk gait system, we detected functional
improvements in certain parameters after cell transplanta-
tion. Partial rescue effects in stride length (e.g., WT[LF]
80.46 ± 1.22 mm, transgenic [TG][LF] 71.18 ± 2.59 mm;
p[LF] = 0.014) were detected in animals that had received
GFP (LF 74.74 ± 1.36 mm, p[LF] versus WT = 0.231) or
BDNF-GFP (LF 72.97 ± 2.54 mm, p[LF] versus WT =
0.071) cell transplants. In contrast, lateral support (WT
0.55% ± 0.36%, TG 5.67% ± 1.94%, p = 0.041) was partially
rescued only by BDNF-GFP cells (5.43% ± 1.47%, p versus
WT = 0.064) (Figure 4F and Table S2).
Transplantation of NPCs into the N171-82Q Mouse
Model Exerts Beneficial Effects in the CatWalk Test
Similar to cell transplantation into R6/2 mice, the robust
Rotarod assay as well as the grip strength test revealed no
differential effects by transplanted NPCs compared with
vehicle-injected N171-82Q animals (n = 10–12/group) (Fig-
ures 5A and 5B; experimental outline Figure 1B, lower
panel). Furthermore, the lack of body weight gain in trans-
genic animals could not be rescued (Figure 5D) and the
open field test did not result in significant reduction offor cell groups 3 time (p = 0.076). BDNF-GFP NPCs did not differ
from non-lesioned animals (p = 0.144), but GFP NPC-grafted (p =
0.022) and non-grafted animals (p = 0.009) were significantly
different from non-lesioned animals. *p < 0.05, ***p < 0.001.
(D) Analysis of Rotarod performance at an age of 18 weeks (8 weeks
after transplantation). Only lesioned, non-grafted animals were
significantly different to non-lesioned mice (p = 0.023), showing
a beneficial effect of transplanted cells on Rotarod performance.
*p < 0.05 versus PBS + HBSS.
(E) List of affected CatWalk gait parameters, analyzed by one-way
ANOVA with post hoc Tukey’s test between groups for each paw.
At 14 weeks of age, the following parameters were significantly
different (p < 0.05) between lesioned and non-lesioned animals:
walk speed, swing, and swing speed. NPCs affected beneficially
swing and swing speed. At 18 weeks of age, the following param-
eters were additionally significantly different: cadence, stride
length, stand, and duty cycle. RH, right hindpaw; LF, left forepaw;
LH, left hindpaw.
Data represent mean (n = 10 animals) ± SEM. For explanatory
graphs and statistics, see Figure S1.
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Figure 4. Few Gait Parameters of the R6/2 Model Are Affected by Transplantation of NPCs
(A) Behavioral performance on the Rotarod was assessed every 2 weeks. R6/2 mice show significantly lower latency to fall from the Rotarod
compared with wild-type (WT) mice after transplantation starting at 6 weeks of age (**p < 0.01). No effect of transplanted NPCs on
transgenic R6/2 mice was observed at any time point.
(B) Paw clasping was analyzed weekly. R6/2 mice had a significantly higher clasping score compared with WT animals at 12 weeks of age.
Cell transplantation did not have any effect on performance in the paw-clasping test.
(C) Grip strength of WT and R6/2 mice was measured at 8 and 12 weeks of age. Non-treated and grafted R6/2 mice displayed a significant
decrease in grip strength at both time points. No effect of transplanted NPCs was observed.
(D) Quantification of total distance of WT and R6/2 mice in the open field.
(E) Body weight was measured weekly. ANOVA with repeated measures (cell groups 3 time, p = 0.001) and consecutive simple effects
analysis with Sidak correction show a significant decrease of body weight in all transgenic R6/2 compared with WT animals from 10 weeks
of age on.
(F) Gait parameters of R6/2 mice were analyzed on the CatWalk at 10 weeks of age, revealing differences in stride length and lateral
support. Stride length of R6/2 mice was partially rescued by transplantation of NPCs, except for the right hindpaw. Lateral support of R6/2
mice was partially decreased when BDNF-GFP NPCs were transplanted. Values of bars with a different letter (a or b) were significantly
different (p < 0.05) from each other. Values of bars with the same letter (a or b) were not significantly different from each other, hence
values of bars marked with ‘‘ab’’ (marked in red) are not significantly different from either a or b, which indicates a partial/incomplete
rescue of the phenotype. RF, right forepaw; RH, right hindpaw; LF, left forepaw; LH, left hindpaw.
Data represent mean (n = 10–12 animals) ± SEM; *p < 0.05, **p < 0.01, ***p < 0.001 versus WT; n.s., not significant.moved distance in transgenic compared with WT animals
(Figure 5C). Hence, a visible improvement due to NPC
transplantation was not detectable.698 Stem Cell Reports j Vol. 7 j 693–706 j October 11, 2016To identify the occurrence of more subtle motoric effects
after cell transplantation, we also established the CatWalk
gait system for the analysis of the N171-82Q mouse line.
Figure 5. Transplantation of NPCs into
the N171-82Q Mouse Model Exerts Bene-
ficial Effects in the CatWalk Test
(A) Analysis of motor behavior on the Ro-
tarod. N171-82Q mice showed a significant
decrease in the latency to fall compared
with WT animals from 12 weeks of age on. No
difference between NPC-transplanted and
non-transplanted mice was detected.
(B) Grip strength of transgenic animals was
not influenced by transplantation of NPCs
at 13 or 18 weeks of age, but was lower than
in WT.
(C) Total distance moved in the open field
was not changed in transgenic animals
compared with WT mice at 13 or 18 weeks of
age. Transplantation of GFP NPCs in trans-
genic N171-82Q animals reduced the dis-
tance moved at both time points compared
with WT mice, but had no effect when
compared with transgenic N171-82Q mice.
(D) Weekly body weight measurement
showed a slow loss of body weight in
transgenic animals, whereas WT mice
gained body weight over time (ANOVA with
repeated measures [cell groups 3 time,
p = 0.001] and consecutive simple effects
analysis with Sidak correction) from 9 weeks
of age on. No difference was detected be-
tween transplanted and non-transplanted
animals.
(E) Overview of different gait parameters as
quantified by the CatWalk test (p < 0.05).
NPCs affected positively altered cadence,
stride length, print area, print length,
maximum intensity of distinct paws, and phase dispersion. For explanatory graphs and statistics, see Figure S2. RF, right forepaw; RH, right
hindpaw; LF, left forepaw; LH, left hindpaw.
Data represent estimated marginal mean (A) or mean (B–D) (n = 10–12 animals) ± SEM; *p < 0.05, **p < 0.01, ***p < 0.001 versus WT; n.s.,
not significant.Indeed, we uncovered many gait parameters, which were
significantly different in N171-82Q transgenic and WT
mice (Figure S2 and Table S2). Affected gait parameters
were cadence (WT 26.41 ± 1.75 steps/s, TG 32.59 ± 1.50
steps/s; p = 0.031), swing (e.g., WT[RF] 0.0761 ± 0.0027 s,
TG[RF] 0.0605 ± 0.0019 s; p = 0.0001), stride length (e.g.,
WT[RF] 88.37 ± 3.39 mm, TG[RF] 73.54 ± 2.82 mm;
p[RF] = 0.01), print area (WT[LF] 24.85 ± 0.98 mm2, TG
[LF] 20.74 ± 1.32 mm2; p = 0.047), print length (e.g., WT
[RF] 8.54 ± 0.18 mm, TG[RF] 7.79 ± 0.19 mm; p[RF] =
0.028), print width (e.g., WT[RF] 8.09 ± 0.14 mm, TG[RF]
6.64 ± 0.24 mm; p[RF] = 0.001), maximum intensity (WT
[RF] 50.14 ± 1.29 a.u., TG[RF] 35.95 ± 2.11 a.u.; p[RF] =
0.001), and phase dispersion (e.g., WT[LF_right hindpaw,
RH] 3.89% ± 1.24%, TG[LF_RH] 11.43% ± 1.72%;
p[LF_RH] = 0.009). This demonstrates that the CatWalkcan be used as a valid system to address motor function
in the N171-82Q mouse line. With this method changes
of defined motoric parameters due to NPC transplantation
were detected. These are summarized in tabular representa-
tion (Figure 5E; for explanatory graphs and statistics see
Figure S2 and Table S2). Most of the parameters—stride
length (e.g., TG + GFP NPCs [RF] 80.46 ± 1.68 mm, p[RF]
versus WT = 0.359; TG + BDNF-GFP NPCs [RF] 77.02 ±
3.71 mm, p[RF] versus WT = 0.058), print area (TG + GFP
NPCs [LF] 22.16 ± 1.04 mm2, p[LF] versus WT = 0.359;
TG + BDNF-GFP NPCs [LF] 22.26 ± 1.01 mm2, p[LF] versus
WT = 0.304), print length (e.g., TG + GFP NPCs [RF] 8.04 ±
0.22 mm, p[RF] versus WT = 0.286; TG + BDNF-GFP NPCs
[RF] 8.32 ± 0.17 mm, p[RF] versus WT = 0.816), phase
dispersion (e.g., TG + GFP NPCs [LF_RH] 8.56% ± 1.39%,
p[LF_RH] versus WT = 0.222; TG + BDNF-GFP NPCsStem Cell Reports j Vol. 7 j 693–706 j October 11, 2016 699
[LF_RH] 8.57% ± 1.92%, p[LF_RH] versus WT = 0.151)—
were partially rescued by both NPC types, and no signifi-
cant difference between transplantation with GFP and
BDNF-GFP cells was measured. However, cadence was
only positively affected after transplantation with BDNF-
GFP NPCs (TG + BDNF-GFP NPCs 31.70 ± 1.53 steps/s,
p versus WT = 0.069).
Cell Survival Is Differentially Altered in NPC-
Transplanted Groups in the Three Mouse Models
Stereotaxic injection of QA into the striatum of C57BL/6J
mice led to an almost complete depletion of MSNs positive
for dopamine- and cyclic AMP-regulated neuronal phos-
phoprotein (DARPP32) (Figure 6A). The lesion volume
did not differ between the groups (QA + HBSS 1.13 ±
0.13 mm3, QA + GFP NPCs 1.09 ± 0.16 mm3, and QA +
BDNF-GFP NPCs 1.17 ± 0.28 mm3, Figure 6B, n = 4/group).
Differentiated ESCs injected into the lesion center 1 week
after lesioning were detected by BrdU staining (Figure 6C)
and, most importantly, showed no sign of tumor forma-
tion. The initial graft contained 100,000 cells, and stereo-
logical estimation (n = 4/group) revealed that 20.10% ±
4.51% BDNF-GFP and 21.65% ± 2.98% GFP NPCs survived
9 weeks after transplantation in the striatum (Figure 6D).
No significant differences were detected between both
transplantation groups. Additionally we investigated
cellular survival for the two geneticmousemodels. Cell sur-
vival in the transgenic R6/2 model (Figure 6E, n = 4/group)
was lower than in the QA model; 9.61% ± 2.96% BDNF-
GFP and 9.78% ± 1.48%GFP cells survived after transplant-
ing 100,000 cells/hemisphere. In contrast, quantification
of transplanted cells in the transgenic N171-82Q model
(Figure 6F, n = 4/group) shows that 17.89% ± 1.09%
BDNF-GFP cells and 10.65% ± 2.52% survived. Here, cell
survival was increased when transplanting BDNF-GFP cells
(p = 0.039). In both transgenic mouse lines (Figures 6G and
6H), BDNF-GFP cells produce BDNF as detected by BDNF-
antibody staining. Under high magnification, BDNF-GFP
can also be detected with the GFP antibody, albeit at an
almost undetectable level (Figure 6H). In contrast, GFP cells
are only positive for GFP without showing BDNF expres-
sion (Figures 6G and 6H).
BDNF-GFP NPCs Differentiate Preferably Toward
Neuronal Cell Fate in the QA-Lesioned Striatum and
Influence Endogenous Neurogenesis
QA-induced lesion was the only HD mouse model that ex-
hibited a robust functional improvement after injection of
BDNF-GFPNPCs. For this reason,we analyzed positiveNPC
effects in detail to elucidate their mechanism of action. To
determine the cell fate of transplanted cells, we double
stained BrdU cells (n = 8 animals/group) with antibodies
against the three neural cell lineages (Figure 7A). Figure 7B700 Stem Cell Reports j Vol. 7 j 693–706 j October 11, 2016shows that 9 weeks after transplantation, the number
of BrdU-positive neurons was significantly higher (p =
0.0446) in BDNF-GFP grafts (MAP2, 56.14% ± 3.83%)
than in GFP grafts (45.88% ± 2.74%). In contrast, the
number of corresponding S100B+ astrocytes (BDNF-GFP
32.29% ± 1.63%, GFP 47.57% ± 6.77%) was decreased
(p = 0.0486). This means that BDNF-GFP NPCs favor
neuronal (MAP2+) over astrocytic (S100B+) differentiation
(p = 0.0001). Only few aspartoacylase (ASPA)-positive
oligodendrocytes were observed in BDNF-GFP grafts
(1.29% ± 0.18%), but fewer (p = 0.0015) than in GFP grafts
(5.50% ± 0.96%). BDNF-GFP NPCs differentiated strikingly
(p = 0.0022) into the striatal lineage, as assessed by staining
for the striatal specific transcription factor forkhead box
protein (FOXP1) (BDNF-GFP graft 42.67% ± 3.55%, GFP
graft 24.00% ± 3.22%). Analysis of DCX immunolabeling
showed no significant difference in the percentage of
DCX-positive cells in BDNF-GFP (1.13% ± 0.79%) and
GFP (5.25% ± 3.44%) grafts.
Endogenous neurogenesis in the dorsal subventricular
zone (SVZ) was increased upon QA lesioning of the stria-
tum, as evaluated by staining (n = 4 animals/group) for
the neuronal precursor marker DCX (Figure 7C). Quantifi-
cation of DCX numbers (Figure 7D) revealed a significant
increase in the number of DCX cells of BDNF-GFP NPCs
grafted (16,430 ± 1,567 cells) and non-grafted, lesioned
(14,690 ± 2,327 cells) animals compared with healthy
(8,335 ± 885 cells) animals. GFP NPC transplantation
(13,210 ± 1,241 cells) did not significantly (p = 0.124) affect
endogenous neural precursor proliferation.DISCUSSION
Stem cell therapy and BDNF supply are two individual ap-
proaches for the treatment of HD. Given that a combina-
tion of both might be particularly promising, we tested
the use of BDNF-overexpressing NPCs, which had been
derived from mouse ESCs. We compared the functional
outcome after transplantation into three different HD
mouse models and observed robust motor improvements
only in the QA toxin-induced lesion model of HD. In
contrast, transplantation into both transgenic HD mouse
models R6/2 and N171-82Q resulted only in minor general
NPC effects.
The standard behavioral paradigm to testmotor function
in the QA model is the apomorphine-induced rotation
assay, which tests the unilateral dysfunction of the striatum
(Bernreuther et al., 2006; Ramaswamy et al., 2007). Further-
more, the Rotarod as a test for motor coordination andmo-
tor learning, which is widely used for QA-lesioned rats, has
been also described for mice with QA lesion (Chiarlone
et al., 2014). With both assays, we detected a functional
Figure 6. Detection of Grafted GFP and BDNF-GFP Expressing NPCs in the Striatum of Chemical and Transgenic HD Mice
(A) Representative photomicrographs of mouse brain sections from lesioned (QA) and non-lesioned (PBS) mice. Immunostaining for
DARPP32 (red) showed that lesioning leads to a widespread loss of medium spiny neurons in the striatum. Dotted lines indicate lesioned
area. Scale bars, 500 mm.
(B) Quantitative analysis showed that lesion volume does not differ (p = 0.97) between vehicle-treated and transplanted groups (n = 4
animals). Values are expressed as mean ± SEM.
(C–F) Representative micrographs for all three mouse models are shown in (C). GFP cells are positive for BrdU and showed robust GFP
expression. However, GFP signal of BDNF-GFP expressing cells is very weak and almost undetectable by confocal microscopy, but cells could
be efficiently traced by BrdU. Scale bars, 250 mm. Dotted lines indicate the lateral ventricle (LV). Graphs show quantification of cell survival
(n = 4 animals) in the QA (D), the R6/2 (E), and N171-82Q (F) mouse models. Cell survival in the QA and R6/2 model is not different
between BDNF-GFP and GFP transplanted cells, whereas in the N171-82Q model cell survival was significantly increased (p = 0.039) by
transplanting BDNF-GFP cells. Data represent mean ± SEM; *p < 0.05.
(G and H) Grafts (dotted lines) of GFP and BDNF-GFP expressing NPCs (G) in the striatum (Str) of R6/2 mice 7 weeks after cell trans-
plantation at low magnification (Scale bars, 250 mm), or (H) in N171-82Q mice 9 weeks after cell transplantation at higher magnification
(Scale bars, 50 mm). Representative micrographs prove BDNF expression in BDNF-GFP NPCs with very weak detection of GFP signal at higher
magnification (lower panels in G and H). In contrast, BDNF-signal was absent in GFP expressing cells (upper panels in G and H). LV, lateral
ventricle.
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Figure 7. BDNF-GFP Cells Grafted into the QA-Lesioned Striatum Showed Enhanced Neuronal Differentiation and Preserved Adult
Neurogenesis of the SVZ
(A) Maximum-intensity projections of confocal micrographs of BDNF-GFP and GFP grafted cells. Transplanted cells were detected with BrdU
staining (red) and were positive for DCX, MAP2, FOXP1, S100B, and ASPA (all in blue). Scale bar, 100 mm.
(B) Corresponding counts of double-positive cells (n = 8 animals). BDNF-GFP cells differentiated significantly more into a neuronal (MAP2+,
p = 0.0446) and striatal (FOXP1+, p = 0.0022) lineage compared with GFP cells, whereas GFP cells differentiated more into the glial (S100B+,
p = 0.0486 and ASPA+, p = 0.0015) lineage compared with BDNF-GFP cells. In addition, BDNF-GFP cells favored highly significant neuronal
(MAP2+) differentiation over astrocytic (S100B+) differentiation (xxxp = 0.0001 versus BDNF-GFP MAP2). Values represent mean ± SEM;
*p < 0.05, **p < 0.01.
(legend continued on next page)
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improvement after transplantation of BDNF-GFP NPCs.
Instead, GFP NPCs were only supportive when animals
were tested in the Rotarod. Both types of NPCs exerted
beneficial effects on evaluation of distinct CatWalk gait pa-
rameters. The CatWalkmethod is an automated, computer-
ized gait analysis technique that allows objective analysis
of very confined motor function. In HD research, it has
so far only been described for the analysis of the R6/2
mouse model (Chiang et al., 2010) and HD transgenic
rats (Vandeputte et al., 2010). Our data show that the
CatWalk assay is also a valuable behavioral paradigm for
the analysis of the QA-lesioned mouse model. Specific
gait characteristics (walk and swing speed, swing, cadence,
stride length, duty cycle) were significantly different inQA-
lesioned and non-lesioned mice. Furthermore, we estab-
lished the CatWalk gait system for the N171-82Q mouse
model and were able to show that multiple gait parameters
were significantly changed when comparingWTand trans-
genic mice. With this tool, we further identified functional
improvements after transplanting NPCs into N171-82Q
mice, which we were not able to detect with the Rotarod
and grip strength tests. Therefore, we assume that the
CatWalk system is a more sensitive assay for detection of
subtle, but profound, well-defined motor functions, which
can be related to patients’ symptoms. Besides chorea, HD
patients display a more general progressive deterioration
of skilled movements, which may also affect essential mo-
tor skills such asmanual dexterity, locomotion, and specific
gait parameters (Foltstein et al., 1983; Koller and Trimble,
1985). The CatWalk test is able to detect these gait impair-
ments in mice. Other behavioral measures, such as the Ro-
tarod test, detect general coordination, especially chorea.
With our transplant intervention, we were able to detect
partial improvements in several gait parameters. However,
due to small differences in absolute values betweenWTand
transgenic animals, it was difficult to reveal intermediate
improvements, such as those between BDNF-GFP and
GFP transplants. In most gait parameters, both NPC types
partially rescued the pathological phenotype, but effects
were not different when comparing both transplant
groups. However, cadence, as a single gait parameter,
was only positively affected by BDNF-GFP cells in the
N171-82Q mouse model. In contrast to N171-82Q mice,
the R6/2 line behaved differently on the CatWalk, where
only stride length and lateral support were significantly
changed, which is in agreement with published data(C) Representative sections through the SVZ of NPC-transplanted, vehi
and DAPI (blue). Scale bar, 200 mm.
(D) Stereological counts through the dorsolateral SVZ of BDNF-GFP NP
mice (n = 4 animals). A significant increase in the number of DCX ce
animals (p = 0.039) compared with non-lesioned mice was detected. T
cells, but not significantly (p = 0.124). Values represent mean ± SEM(Chiang et al., 2010). Both gait parameters could be
partially rescued either by GFP or BDNF-GFP cells, or by
both NPC types. In general, we did not detect a consider-
able improvement of functional recovery in the R6/2
mouse line, as the two vigorous behavioral paradigms
Rotarod and paw clasping were unchanged.
One possible explanation for the differential behavioral
improvements in the three distinct HD mouse models
could be the different cell survival rate with the highest sur-
vival rate in QA-lesioned animals. NPCs transplanted into
transgenic animals generally displayed lower cell survival,
a phenomenon that has already been demonstrated in
other publications (Ebert et al., 2010; El-Akabawy et al.,
2012; Snyder et al., 2010), possibly due to the progressive
pathology in transgenic mice. Particularly after transplan-
tation into R6/2 animals, approximately only half of the
cells compared with QA-lesioned animals were detectable.
Transplantation into the N171-82Qmice resulted in an in-
termediate cell survival rate compared with both other
mouse models. Interestingly, only in the N171-82Qmouse
model we detected a difference in the cell survival rate of
both NPC types. Here, BDNF-GFP cells survived better
than GFP cells, whichmight explain whymore gait param-
eters are significantly changed by BDNF-GFP NPCs
compared with the R6/2 line. Furthermore, the different
degree of survival may be explained by the fact that in
the transgenic lines the absence of a lesion leads to a
densely packed graft core, which might hinder survival,
migration, and integration of grafted cells (Behrstock
et al., 2008). Although transgenic mouse models are genet-
ically more accurate and neurodegeneration is progressive,
they still lack the feature of extensive neuronal cell death,
which seems to be a prerequisite for survival and integra-
tion of transplanted cells (Labandeira-Garcia et al., 1991;
Watts and Dunnett, 1998) Therefore, most of studies ad-
dressing cellular therapies for HD used QA-lesioned rodent
models, which display massive and predictable cell loss
(Aubry et al., 2008; Bernreuther et al., 2006; Ma et al.,
2012; Shin et al., 2012). Only few cell transplantation
studies with different types of stem or progenitor cells
used transgenic HD mouse models and obtained minor or
no motoric outcome. Especially with the R6/2 line, it was
difficult to obtain any kind of improvement (El-Akabawy
et al., 2012; Fink et al., 2013), whereas N171-82Q seemed
to be the more appropriate transgenic model for cell trans-
plantation (Ebert et al., 2010; Snyder et al., 2010). We cancle-treated, and non-lesioned animals immunostained for DCX (red)
C-grafted, GFP NPC-grafted, non-grafted lesioned, and non-lesioned
lls of BDNF-GFP NPC-grafted (p = 0.010) and non-grafted, lesioned
ransplantation of GFP NPCs also led to an increase in number of DCX
; *p < 0.05, **p < 0.01.
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affirm these observations with our CatWalk data, as more
gait parameters were changed by NPC transplantation in
N171-82Q mice than in the R6/2 line. Both mouse models
differ in the extent of their neuropathology, life span,
and, most importantly, disease progression. Compared
with N171-82Q mice, R6/2 animals display a very drastic,
accelerative phenotype with a very short life span of
12 weeks, which could hinder cellular survival, proper dif-
ferentiation, and functional integration after transplanta-
tion. In conclusion, toxin-induced lesions, causingmassive
cell death, serve as the most appropriate HD mouse model
for cellular transplantation to date. Even if not optimal in
terms of acute cell death, clear positive effects of BDNF
NPCs were obtained in the present study. For this reason,
we analyzed the mode of action of BDNF NPCs in the
QA-lesion model. NPCs expressing either GFP or BDNF-
GFP similarly survived grafting, and no differential effect
of proliferation was observed. Furthermore, due to the
use ofMACS purification, no tumor formationwas induced
by either cell type. Instead, in vivo differentiation was
affected in a cell-type-specific manner. BDNF-expressing
progenitors mainly differentiated into neurons compared
with GFP control cells, which favored glial, and specifically
astrocytic lineage differentiation. Enhanced neuronal
and GABAergic differentiation by BDNF has been already
shown by us and others (Butenscho¨n et al., 2016; Leschik
et al., 2013; Ortega and Alcantara, 2010; Trzaska and Ra-
meshwar, 2011). Furthermore, BDNF is known to be an
important factor for the postnatal growth of the striatum
(Rauskolb et al., 2010) and is essential for the in vitro and
in vivo differentiation of striatal neurons (Gokce et al.,
2009; Ivkovic and Ehrlich, 1999). Indeed, we found more
neurons positive for the striatal marker FOXP1 in BDNF
cell grafts than in GFP cell grafts, which underlines the
HD therapeutic potential of BDNF NPCs.
FOXP1 labels striatal precursors and differentiated MSNs
(Delli et al., 2013). Diverse studies thus far have attempted
to pre-differentiate stem cells into transplantable striatal
progenitors or MSNs by using various kinds of differentia-
tion protocols. Human ESCs were demonstrated to termi-
nally differentiate into GABAergic DARPP32-positive neu-
rons in vitro and in vivo by the use of sonic hedgehog
and BDNF as key molecules (Aubry et al., 2008; Ma et al.,
2012). Therefore, our approach with mouse ESCs was to
analyze whether very early PSA-NCAM-positive neural pro-
genitors, which expressed one of the earliest telencephalic
markers FOXG1, could differentiate in vivo into MSNs
through continuous BDNF supply. To obtain NPCs, we
used the differentiation protocol of Bernreuther et al.
(2006) with minor modifications. This study used mouse
ESC-derived L1-overexpressing NPCs in QA-lesioned
mice, which led to short-term functional improvement.
Here, we show that functional improvement was accompa-704 Stem Cell Reports j Vol. 7 j 693–706 j October 11, 2016nied by increased striatal differentiation of BDNF NPCs,
meaning that BDNF as signaling molecule is sufficient
to trigger in vivo differentiation into MSNs. Likewise, for
in vitro striatal differentiation of human ESCs, alterna-
tively the potent telencephalic morphogen sonic hedge-
hog could be used at early stages of differentiation to obtain
MSNs after transplantation (Danjo et al., 2011).
In addition to the analysis of in vivo differentiation of
transplanted cells, precursor proliferation of endogenous
DCX-positive cells was investigated as a potential mecha-
nism leading to improved motor behavior. It is known
that striatal QA lesion by itself induces proliferation and
migration of adult neuronal stem cells from the dorsal
SVZ as an attempt to regenerate the lesioned striatum (Tat-
tersfield et al., 2004). BDNF is known to be an important
trigger of adult neurogenesis (Vilar and Mira, 2016).
Therefore, transplantation of BDNF-expressing cells could
induce a higher migration rate, better survival, increased
proliferation, and/or differentiation of SVZ precursor cells.
However, we found no difference in the number of DCX-
positive cells in QA-lesioned animals with or without
BDNF cell transplants, which implies that BDNF exerted
no positive effect on endogenous progenitors. Interest-
ingly, GFP transplants significantly reduced the number
of DCX cells. In conclusion, this would mean that NPC
transplantation by itself induces negative changes in tissue
homeostasis or endogenous regeneration, which might
be overcome by BDNF. The differences in the motoric
outcome after transplantation of both cell types could
hence be due to a combination of BDNF-positive effects
on differentiation of transplanted cells and its preserving
effects on lesion-induced SVZ neurogenesis.EXPERIMENTAL PROCEDURES
For a more detailed description, see Supplemental Experimental
Procedures.
Differentiation of ESCs
V6.5 mouse ESCs were modified by knockin technology into the
Rosa26 locus to overexpress either BDNF-GFP or GFP, differentiated
into NPCs as described previously with minor modifications, and
purified with MACS (Butenscho¨n et al., 2016; Leschik et al., 2013).
To ensure cell detection after transplantation, we treated cells with
5 mM BrdU (Sigma-Aldrich) for 48 hr before transplantation.
Cell Transplantation
All experiments were carried out in accordance with the European
Union Council Directive of 22 September 2010 (2010/63EU) and
were approvedby the local animal care committee (Landesuntersu-
chungsamt Koblenz, permit numberG 12-1-097).We transplanted
100,000 cells into the right striatum of QA-lesioned mice and
100,000 cells per striatum bilaterally into R6/2 and N171-82Q
mice.
Behavioral Assays
Motor behavior of all mice was tested with the Rotarod, and gait
parameters were defined with the CatWalk system. Moreover,
QA-lesioned mice were tested with the rotation assay. Both
transgenic mouse lines were tested in the open field and grip
strength paradigm. Additionally R6/2mice were tested for clasping
performance.
Immunofluorescent Staining
Immunocytochemistry was performed using the following
primary antibodies: Nestin, PSA-NCAM, MAP2, OLIG2, KI67,
DCX, GFAP, FOXG1, BrdU, and GFP. For immunohistochemistry
we used the following antibodies: BrdU, FOXP1, GFAP, S100B,
MAP2, BDNF, and GFP. The appropriate secondary Alexa-Fluor
antibodies were applied.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures, two figures, and two tables and can be found with
this article online at http://dx.doi.org/10.1016/j.stemcr.2016.
08.018.
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